CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Two-Year Outcomes After Sirolimus-Eluting Stent Implantation
Results From the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) Trial
Giora Weisz, MD*,
Martin B. Leon, MD*,*,
David R. Holmes, Jr, MD ,
Dean J. Kereiakes, MD ,
Mel R. Clark, MD ,
Barry M. Cohen, MD¶,
Stephen G. Ellis, MD||,
Patrick Coleman, MD#,
Carolyn Hill**,
Chunxue Shi, MS,
Donald E. Cutlip, MD,
Richard E. Kuntz, MD, MSc and
Jeffrey W. Moses, MD*
* Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York
Saint Mary's Hospital, Rochester, Minnesota
Ohio Heart Health Center, Cincinnati, Ohio
Intergris Oklahoma Heart Center, Oklahoma City, Oklahoma
¶ Morristown Memorial Hospital, Morristown, New Jersey
|| Cleveland Clinic Foundation, Cleveland, Ohio
# Northern California Research Association, Santa Rosa, California
** Cordis (Johnson & Johnson), Warren, New Jersey
Harvard Clinical Research Institute, Boston, Massachusetts
Beth Israel Deaconess Medical Center, Boston, Massachusetts
Brigham and Women's Hospital, Boston, Massachusetts
Manuscript received January 9, 2005;
revised manuscript received October 28, 2005,
accepted November 7, 2005.
* Reprint requests and correspondence: Dr. Martin B. Leon, Center for Interventional Vascular Therapy, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 5th Floor, New York, New York 10032
(Email: mleon{at}crf.org).
OBJECTIVES: The purpose of this study was to examine the two-year clinical outcomes in patients enrolled in the Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) study.
BACKGROUND: The SIRIUS study was a double-blinded randomized study which demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS).
METHODS: Patients with de novo native coronary artery lesions randomized to either SES (533 patients) or control BMS (525 patients) were followed for two years.
RESULTS: Between one and two years, there were infrequent additional clinical events that were equally distributed between the sirolimus and control groups. After two years, target lesion revascularization was 5.8% and 21.3% in SES and control patients, respectively (p < 0.001), and major adverse cardiovascular events and target vessel failure rates were 10.1% versus 24.4% and 12.0% versus 26.7%, respectively (p < 0.0001 for both). There were no differences in death, myocardial infarction, and stent thrombosis between the two groups.
CONCLUSIONS: Clinical outcomes two years after implantation of SES continue to demonstrate significant reduction in the need for repeat target lesion (and vessel) revascularization compared with BMS without evidence for either disproportionate late restenosis or late stent thrombosis.
|
Abbreviations and Acronyms
| | BMS = bare-metal stents | | LAD = left anterior descending coronary artery | | MACE = major adverse cardiac event | | PES = paclitaxel-eluting stents | | SES = sirolimus-eluting stents | | SIRIUS = Sirolimus-Eluting Stent in De Novo Native Coronary Lesions | | TLR = target lesion revascularization | | TVF = target vessel failure | | TVR = target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
J. G. Byrne, M. Leacche, D. E. Vaughan, and D. X. Zhao
Hybrid Cardiovascular Procedures
J. Am. Coll. Cardiol. Intv.,
October 1, 2008;
1(5):
459 - 468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Malenka, A. V. Kaplan, F. L. Lucas, S. M. Sharp, and J. S. Skinner
Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents
JAMA,
June 25, 2008;
299(24):
2868 - 2876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kelbaek, L. Klovgaard, S. Helqvist, J. F. Lassen, L. R. Krusell, T. Engstrom, H. E. Botker, E. Jorgensen, K. Saunamaki, S. Aljabbari, et al.
Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions: 3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) Trial
J. Am. Coll. Cardiol.,
May 27, 2008;
51(21):
2011 - 2016.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. C. Marroquin, F. Selzer, S. R. Mulukutla, D. O. Williams, H. A. Vlachos, R. L. Wilensky, J.-F. Tanguay, E. M. Holper, J. D. Abbott, J. S. Lee, et al.
A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications
N. Engl. J. Med.,
January 24, 2008;
358(4):
342 - 352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
270 - 285.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli, G. Campo, C. Arcozzi, P. Malagutti, R. Carletti, F. Ferrari, D. Barbieri, G. Parrinello, G. Percoco, and R. Ferrari
Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction: Results From the STRATEGY Study
J. Am. Coll. Cardiol.,
July 10, 2007;
50(2):
138 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Cutlip, S. Windecker, R. Mehran, A. Boam, D. J. Cohen, G.-A. van Es, P. Gabriel Steg, M.-a. Morel, L. Mauri, P. Vranckx, et al.
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Circulation,
May 1, 2007;
115(17):
2344 - 2351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Med.,
April 1, 2007;
12(2):
63 - 64.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Camenzind, P. G. Steg, and W. Wijns
A Cause for Concern
Circulation,
March 20, 2007;
115(11):
1440 - 1455.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-P. B.-L. Rocca, C. Kaiser, M. Pfisterer, and on behalf of the BASKET Investigators
Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET)
Eur. Heart J.,
March 2, 2007;
28(6):
719 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Meier, R. Zbinden, M. Togni, P. Wenaweser, S. Windecker, B. Meier, and C. Seiler
Coronary Collateral Function Long After Drug-Eluting Stent Implantation
J. Am. Coll. Cardiol.,
January 2, 2007;
49(1):
15 - 20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Nordmann, M. Briel, and H. C. Bucher
Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis
Eur. Heart J.,
December 1, 2006;
27(23):
2784 - 2814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tsimikas
Drug-Eluting Stents and Late Adverse Clinical Outcomes: Lessons Learned, Lessons Awaited
J. Am. Coll. Cardiol.,
May 16, 2006;
47(10):
2112 - 2115.
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Sigwart
Drug-Eluting Stents Are Safe and Effective: Right or Wrong?
J. Am. Coll. Cardiol.,
April 4, 2006;
47(7):
1361 - 1362.
[Full Text]
[PDF]
|
|
|
|
